Our long-term goal is to improve the efficacy of EGFR family-directed monoclonal antibody therapy with the overarching hypothesis that antibodies can be combined with other anti-tumor agents to promote host- protective adaptive immunity that improves cancer therapy. In the current funding period we have 1) defined tumor cell based determinants of anti-tumor efficacy and promotion of antibody-dependent cellular cytotoxicity (ADCC) such as c-Abl and protein kinase C-?, 2) demonstrated that effective antibody therapy promotes host-protective immune responses, and 3) employed a novel shRNA library screening strategy to identify Tex9 and other tumor cell-based determinants of immune rejection. We now propose to translate these findings into the clinic, and to develop innovative new approaches to improve antibody-initiated tumor rejection.
The first aim i s to define EGFR network-related signaling following therapy with cetuximab, nilotinib or the combination in a Phase I clinical tria of these drugs in patients with solid tumors.
The second aim i s to enhance antibody-dependent cellular cytotoxicity (ADCC) and improve its in vivo anti-tumor effects. We will test the hypotheses that 1) nilotinib therapy or protein kinase C-? knockdown enhance ADCC and subsequent antigen presentation, and 2) strategies to enhance ADCC promote the anti-tumor effects of cetuximab.
The third aim i s to identify new tumor cell-based molecular determinants of immune rejection in murine models. We have screened a barcoded murine whole-genome shRNA library in vivo and identified genes whose knockdown in EO771 breast tumor cells selectively enriches or depletes such cells in tumors in NSG, WT C57Bl/6 and SCID C57Bl/6 mice. We hypothesize that in vivo genomic screening can identify new targets that alter immune rejection initiated by monoclonal antibody therapy or vaccination. The successful execution of this work will have high impact by 1) defining the value of synthetic lethal screening to identify MAb-based combinations (Aim 1), 2) demonstrating new ways to promote ADCC-induced host protection (Aim 2), and 3) defining new targets and pathways that regulate tumor cell-based sensitivity and resistance to antibody-initiated host immunity (Aim 3). These results will have resonance for the field of tumor immunity.

Public Health Relevance

Monoclonal antibodies (MAb) are useful treatments for many tumor types, but new approaches are needed to improve therapy outcomes.
We aim to improve the ability of MAb to directly kill cancer cells, and to stimulate the body's immune system so that people can be immunized against their cancers to prevent or delay relapse or disease worsening.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA050633-27
Application #
9204804
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Yovandich, Jason L
Project Start
1989-06-01
Project End
2018-12-31
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
27
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Berens, E B; Sharif, G M; Schmidt, M O et al. (2016) Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene :
Zhang, Y-W; Nasto, R E; Varghese, R et al. (2016) Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene 35:1643-56
Weiner, Louis M (2015) Cancer immunology for the clinician. Clin Adv Hematol Oncol 13:299-306
AlDeghaither, Dalal; Smaglo, Brandon G; Weiner, Louis M (2015) Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol 55 Suppl 3:S4-20
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Redman, J M; Hill, E M; AlDeghaither, D et al. (2015) Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67:28-45
Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26
Surana, Rishi; Wang, Shangzi; Xu, Wei et al. (2014) IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. Cancer Immunol Res 2:1103-12
Murray, Joseph C; Aldeghaither, Dalal; Wang, Shangzi et al. (2014) c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res 2:1186-98
Shivapurkar, Narayan; Weiner, Louis M; Marshall, John L et al. (2014) Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One 9:e84686

Showing the most recent 10 out of 49 publications